The Action Is Good, It's Still a Downtrend<br />By Rev Shark<br />RealMoney.com Contributor<br />2/28/2008 8:51 AM EST <br /><br /><br />The tragic or the humorous is a matter of perspective. <br />-- Arnold Beisser<br /><br />It can be quite helpful to consider the stock market from a variety of different perspectives. Things can look quite different if you just slightly adjust the things you are looking at. <br /><br />For example, Doug Kass notes that the DJIA is 10% off the low it saw on the SocGen mess on Jan. 22. That accounting is correct, but if you eliminate those two days of wild action following the Martin Luther King holiday when the Fed cut, the Nasdaq is very close to unchanged from where it was on Jan. 18 and is barely off its closing lows. It would be quite a stretch to call the action since Jan. 23 a meaningful rally, but that seems to be the perspective of many market players. <br /><br />The other major indices have done a bit better than the Nasdaq, but if you look at the big picture without the unusual spikes of those two crazy days in January, it is pretty clear that the market has gone nowhere. Some individuals stocks have certainly done well, as is always the case in any market, but overall we are bouncing along near the lows and struggling very hard to turn up. <br /><br />What has been interesting about the last few days is that the market has been holding up very well despite the quite poor news flow. We aren't seeing intense selling as more negatives are pondered, but market players are bottom-fishing some of the stocks that have not bounced at all, such as Apple (AAPL) and Google (GOOG) . <br /><br />This makes a good argument for the proposition that the bottom is in, and if you consider that the market has been holding in a trading range for over a month now, an upside bet doesn't seem like too bad an idea. <br /><br />On the other hand, the bigger downtrend is still clearly intact and if you consider how lame the bounce has been with the distraction of the SocGen mess, it is easy to conclude that the market is still in poor health. <br /><br />While I like seeing the market shrug off bad news and hold within a trading range, I still don't have any great confidence that we have the juice to commence a better and more lasting uptrend. We have been churning recently, and while that helps us build support, the buyers need to show more sustained resolve. <br /><br />I'll stay open-minded, but I see no reason to change my opinion that we are enjoying nothing more than a respite within a bear trend. <br /><br />We have a soft start as we await the second day of testimony by Ben Bernanke. The news flow is slow and overseas markets are mostly negative. <br />--------------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: AVCI +16.0%, DBRN +12.9%, NKTR +11.5%, LSR +8.7%, CRM +8.6%, CTRP +7.2%, MIDD +7.0%, VISN +6.7%, BRKR +6.0%, NRF +5.5%, FLS +5.4%, FLR +5.3%, MANT +4.5%, NUVO +3.6%, LTD +3.3%, AHT +3.1%, ZINC +3.1%, GEF +2.6%, UHT +1.8%, TELK +1.5%, GIFI +1.3%, MRX +1.2%... Other news: IMMC +22.2% (announces FDA clearance of the CellSearch circulating tumor cell kit for monitoring patients with metastatic prostate cancer), VRNM +12.8% (awarded U.S. Department of Energy grant to speed enzyme development for cellulosic ethanol production), DARA +10.0% (continued momentum from yesterday, announces appointment of new director to board), LTON +8.3% (PT Media Nusantara Citra extends tender offer for 6 mln ADS at $3.80), REGN +8.3% (announces that the FDA approves co's ARCALYST for treatment of cryopyrin-associated periodic syndromes), WPL +7.0% (has retained Merrill Lynch to review strategic alternatives; co postpones earnings release), XNPT +6.9% (Xenoport and GlaxoSmithKline report 'positive' top-line results of final pivotal trial of XP13512/GSK1838262 for restless legs syndrome), EOG +5.5% (still checking), RMBS +3.3% (still checking), APPL +2.5% (presents at Goldman Sachs conference; on track to sell 10 mln iPhones this year, unlocked phones are sign of great demand ), LVLT +2.5% (Level 3 and IBM announce patent cross-license)<br /><br />Allapoole avanevad:<br /><br />In reaction to weak earnings/guidance: SEED -33.5% (also announces it has licensed a new genetically modified corn to officially introduce the next generation of corn product into China), AIRN -17.2%, PDGI -16.1%, FIRE -12.1% (also announces Wayne Jackson to step down as CEO), S -11.3%, DRCO -9.4%, MYL -8.7%, SFI -8.1%, ESPD -7.9%, WG -5.6%, AMSF -5.4%, COWN -4.3%, WNR -4.0%, GSIG -3.8%, GMR -3.0%, GMKT -2.9%, SWX -2.8%, IPGP -2.4%, CEDC -2.4%, SHLD -2.1%, TS -1.8%, CDR -1.8%, ARNA -1.3%... Select gold stocks showing weakness despite higher spot prices: DROOY -2.6%, GFI -1.8%, GOLD -1.7%, AAUK -1.4%... Other news: NGSX -39.7% (announces preliminary results from second Phase 3 clinical trial in HIV-DSP; primary and secondary endpoints do not achieve statistical significance), TMA -22.0% (may have to sell assets to meet margin calls), YTEC -4.2% (raises target of nation-wide POS installation base from 20k to 25k by the end of 2008), DHI -4.1% (down in sympathy with TMA), DSTI -3.9% (CFO Raja Venkatesh resigns, effective March 14), IMB -3.2% (still checking), UBS -3.0% (still checking), NNN -2.5% (prices offering of convertible notes; common stock or a combination thereof at an initial conversion price of $25.42 per share), FRX -1.5% (announces amendment to Bystolic Agreement; announces FRX will commercialize, develop and distribute Bystolic),